The study and its comparison
One hundred nineteen people with mild-to-moderate Alzheimer disease were randomized to placebo or resveratrol for 52 weeks. The dose increased from 500 mg daily to 1,000 mg twice daily. [1]
Resveratrol and metabolites were detectable in cerebrospinal fluid. Some amyloid trajectories differed, and brain-volume loss was greater with resveratrol. Common adverse effects included nausea, diarrhea and weight loss. [1]
What the finding establishes
The paper called for further interpretation of these biomarker changes. Neither entry into cerebrospinal fluid nor a changed amyloid measure establishes meaningful clinical improvement. Funding and full conflicts were not established from the retrieved abstract. The regimen does not support self-treatment of dementia. [1]
A hypothetical distinction
Imagine a compound reaches its proposed target tissue. Delivery is only one step toward demonstrating patient benefit.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.